These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm. Tabriz HM; Adabi Kh; Lashkari A; Heshmat R; Haghpanah V; Larijani B; Tavangar SM Pathol Res Pract; 2009; 205(2):83-7. PubMed ID: 18996649 [TBL] [Abstract][Full Text] [Related]
9. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration? Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553 [TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-beta type II receptors and smad proteins in follicular thyroid tumors. West J; Munoz-Antonia T; Johnson JG; Klotch D; Muro-Cacho CA Laryngoscope; 2000 Aug; 110(8):1323-7. PubMed ID: 10942134 [TBL] [Abstract][Full Text] [Related]
11. [Expression and clinical significance of galectin-3 in well-differentiated thyroid carcinoma]. Ouyang D; Chen FJ; Wei MW; Yang AK; Chen ZQ; Li QL; Chen YF Ai Zheng; 2005 Nov; 24(11):1367-71. PubMed ID: 16552965 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of MIB-1 immunoreactivity and nucleolar organizer regions in nonneoplastic and neoplastic thyroid lesions. Lewy-Trenda I; Bieńkiewicz M Pol J Pathol; 1999; 50(3):129-38. PubMed ID: 10624114 [TBL] [Abstract][Full Text] [Related]
13. The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma. Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M Exp Oncol; 2006 Mar; 28(1):70-4. PubMed ID: 16614712 [TBL] [Abstract][Full Text] [Related]
14. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators. Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527 [TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma. Resnick MB; Schacter P; Finkelstein Y; Kellner Y; Cohen O Mod Pathol; 1998 Aug; 11(8):735-9. PubMed ID: 9720501 [TBL] [Abstract][Full Text] [Related]
16. Galectin-3 is a presurgical marker of human thyroid carcinoma. Orlandi F; Saggiorato E; Pivano G; Puligheddu B; Termine A; Cappia S; De Giuli P; Angeli A Cancer Res; 1998 Jul; 58(14):3015-20. PubMed ID: 9679965 [TBL] [Abstract][Full Text] [Related]
17. Assessment of cyclin D1 gene expression as a prognostic factor in benign and malignant thyroid lesions. Brzeziańska E; Cyniak-Magierska A; Sporny S; Pastuszak-Lewandoska D; Lewiński A Neuro Endocrinol Lett; 2007 Aug; 28(4):341-50. PubMed ID: 17693985 [TBL] [Abstract][Full Text] [Related]
18. The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer. Wang S; Lloyd RV; Hutzler MJ; Safran MS; Patwardhan NA; Khan A Mod Pathol; 2000 Aug; 13(8):882-7. PubMed ID: 10955455 [TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical localisation of RET and p53 mutant protein of thyroid lesions in a North-Eastern Malaysian population and its prognostic implications. Omar E; Madhavan M; Othman NH Pathology; 2004 Apr; 36(2):152-9. PubMed ID: 15203751 [TBL] [Abstract][Full Text] [Related]
20. HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma. Ito Y; Yoshida H; Tomoda C; Miya A; Kobayashi K; Matsuzuka F; Kakudo K; Kuma K; Miyauchi A Anticancer Res; 2005; 25(1A):179-82. PubMed ID: 15816536 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]